Beneficial effects of fingolimod in MS patients with high serum Sema4A levels

We previously demonstrated that patients with multiple sclerosis (MS) of high serum Sema4A levels are resistant to IFN-β therapy. To further elucidate the role of serum Sema4A as a biomarker for therapeutic stratification in MS patients, it is important to clarify the efficacy of other disease-modif...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Koda, Toru, Namba, Akiko, Nakatsuji, Yuji, Niino, Masaaki, Miyazaki, Yusei, Sugimoto, Tomoyuki, Kinoshita, Makoto, Takata, Kazushiro, Yamashita, Kazuya, Shimizu, Mikito, Fukazawa, Toshiyuki, Kumanogoh, Atsushi, Mochizuki, Hideki, Okuno, Tatsusada
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5843273/
https://ncbi.nlm.nih.gov/pubmed/29518148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0193986
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars